Homepage NewsNews Highlight Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy JIANGSU, China, July 25, 2024 -- Ractigen Therapeutics, a pioneering developer of small activating RNA…ractigenJuly 25, 2024
Company NewsHomepage News Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million…EnvisionJanuary 27, 2022
Company NewsHomepage News Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed…EnvisionFebruary 10, 2021
Company NewsHomepage News CB Insights lists Ractigen as one of the Top RNA biotech companies in China Today, CB Insights China published, for the first time, a top list of RNA biotech…EnvisionMay 19, 2020